Composite and multicomponent end points in clinical trials-Reference-Cited by-同舟云学术

Composite and multicomponent end points in clinical trials

Published:2017-07-04 Issue:28 Volume:36 Page:4437-4440
ISSN:0277-6715
Container-title:Statistics in Medicine
language:en
Short-container-title:Statist. Med.

Author:

Sankoh Abdul J.¹,Li Haihong¹^ORCID,D'Agostino Ralph B.²

Affiliation:

1. Sage Therapeutics; Cambridge MA U.S.A.

2. Boston University; Boston MA U.S.A.

Publisher

Wiley

Subject

Statistics and Probability,Epidemiology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/sim.7386/fullpdf

Reference19 articles.

1. US FDA Multiple endpoints in clinical trials: guidance for industry 2017 https://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM536750.pdf

2. Sankoh AJ An overview of strategies for dealing with composite endpoints in clinical trials San Francisco 2003 334 338

3. Use of composite endpoints in clinical trials;Sankoh;Statistics in Medicine,2014

4. Combined endpoints: can we use them?;Lubsen;Statistics in Medicine,2002

5. Perspectives on composite endpoints;Cannon;Controlled Clinical Trials,1997

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Competing risk multistate censored data modeling by propensity score matching method;Scientific Reports;2024-02-22

2. Correlation between hyperreflective foci and visual function testing in eyes with intermediate age-related macular degeneration;International Journal of Retina and Vitreous;2023-04-07

3. Endpoints: types, selection, interpretation of the results obtained on the example of cardiology studies;Cardiovascular Therapy and Prevention;2022-06-04

4. Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2021-08

5. Nonparametric estimation in an illness‐death model with component‐wise censoring;Biometrics;2021-05-18